Navigation Links
Brain angioplasty and stents found safe and effective for stroke patients
Date:12/10/2012

OAK BROOK, Ill. Some stroke patients may benefit from cerebral angioplasty and stent placement, according to a new study published online in the journal Radiology.

"As many as 70 percent of ischemic stroke patients could have positive clinical outcomes with the additional use of intra-arterial revascularization using stents," said Martin Roubec, M.D., Ph.D., a neurologist in the Comprehensive Stroke Center at the University Hospital Ostrava in the Czech Republic.

Ischemic stroke, the most common form of stroke, occurs when blockage in an arteryoften from a blood clot or a fatty deposit due to atherosclerosisinterrupts blood flow to an area of the brain. According to Dr. Roubec, only a fraction of European patients experiencing an ischemic stroke are treated with a potentially life-saving drug that can dissolve the clot in a procedure called intravenous thrombolysis (IVT).

"Intravenous thrombolysis must be administered within four and a half hours of the onset of a stroke and cannot be used in patients who are taking anticoagulant medication," said David koloudk, M.D., Ph.D., associate professor at University Hospital Ostrava. "Because of these limitations, the majority of ischemic stroke patients receive no therapy at all."

The study involved 131 acute ischemic stroke patients treated over a two-year period at two comprehensive stroke centers in Ostrava and Olomouc. The patients, including 74 men and 57 women (mean age 65.8), all had a blockage in the middle cerebral artery detected by computed tomography (CT) or magnetic resonance imaging (MRI).

Seventy-five patients were treated with IVT; 26 (35 percent) of whom achieved a favorable three-month outcome. The remaining 49 patients, for whom IVT failed to re-open the blocked artery, received either cerebral angioplasty/stent placement or no additional therapy.

Of the 23 patients who underwent angioplasty and stenting, 10 (43.5 percent) achieved a favorable three-month outcome. Of the 26 patients who received no more therapy, four (15.4 percent) had a favorable outcome.

The remaining two groups of patients were ineligible for IVT and received either revascularization treatment or received no further therapy. Of the 31 patients who underwent angioplasty and stent placement, 14 (45.2 percent) achieved a favorable outcome. Of the 25 patients who received no therapy, two (8 percent) had a favorable outcome.

To perform the revascularization procedure, the physicians used an imaging technique called digital subtraction angiography to visualize the blood vessels and a guide wire to maneuver a balloon-tipped catheter to the location of the blockage in the middle cerebral artery. Once the balloon was inflated, deflated and withdrawn, a stent was inserted to help the artery remain open. Patients with a favorable three-month outcome following the procedure were able to live independently and perform normal daily activities.

"We demonstrated that in patients with middle cerebral artery blockage after IVT failure or for whom IVT is contraindicated, revascularization with stents is superior to providing no further therapy," Dr. Roubec said.


'/>"/>

Contact: Linda Brooks
lbrooks@rsna.org
630-590-7762
Radiological Society of North America
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Epilepsy Leads to More Brain Abnormalities Over Time
3. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
4. Why is traumatic brain injury increasing among the elderly?
5. Brain Falters Near End of Life, but Games, Puzzles Might Slow Decline
6. Dental X-Rays May Be Linked to Benign Brain Tumors
7. Nonsurgical Method to Measure Brain Pressure Shows Promise
8. Researchers Map Brain Regions Linked to Intelligence
9. Football-related catastrophic brain injuries on the rise
10. Brain Tumor Vaccine Shows Promise in Early Trial
11. Brain Surgery Might Ease Tough-to-Treat OCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... 26, 2017 , ... As hurricane relief efforts continue throughout ... bras and maternity garments to women in isolated shelters. Distribution is being handled ... affiliation with Black Mothers’ Breastfeeding Association. Leading Lady’s philanthropic donation includes items from ...
(Date:9/26/2017)... ... 26, 2017 , ... SyncDog, Inc. , the leading ... and software house EBF GmbH . Since 1994, EBF has been successfully ... enables SyncDog to distribute EBF Migrator product in the U.S. and Canada. ...
(Date:9/26/2017)... ... September 26, 2017 , ... Global healthcare company ... years, extending the company’s commitment to the world’s first all-diabetes professional cycling team ... company Novo Nordisk partnered with the professional cycling team Team Type 1 to ...
(Date:9/26/2017)... Boston, MA (PRWEB) , ... September 26, 2017 , ... ... of its first office under its new umbrella, CGL Technologies, LLC. , The new ... security industry veterans Remo Patitucci and Jon McCormack, both of whom have creative business ...
(Date:9/26/2017)... ... ... As the holiday season nears, best deals online website, Sutlr ... find tips and stories for products and services savings. With a lot of chaos ... The deals are organized by categories so can easily find what you’re looking for ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... Pa. and KALAMAZOO, Mich. , Sept. 18, ... , and OptiMed Specialty Pharmacy of ... to offer a strategic hub service that expedites and ... sought-after personal spirometer, Spiro PD 2.0, and wellness management ... spirometer is a medical device used to measure lung ...
(Date:9/12/2017)... MOUNTAIN LAKES, N.J. , Sept. 12, 2017  Consumer reviews ... Embrace Hearing as the number one company for hearing ... Oticon™, ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that ...
(Date:9/9/2017)... Lilly and Company (NYSE: LLY ) will ... an investigational, oral, first-in-class molecule for the acute treatment ... placebo in the Phase 3 SPARTAN study. Detailed results ... the International Headache Society (IHC) in Vancouver ... lasmiditan,s potential to reduce pain and provide freedom from ...
Breaking Medicine Technology: